Cited by 685Cystic Fibrosis Research AdvancesGenetic and Kidney Cyst DiseasesNeonatal Respiratory Health Research

The DOI matches its Crossref record; 194 of the 195 references it cites were found in a registry or an index.

Cystic fibrosis

Open access

Shteinberg, Michal, Haq, Iram J, Polineni, Deepika, Davies, Jane C·2021·The Lancet

Open this paper in CoChat — free account

Abstract

Cystic fibrosis is a monogenic disease considered to affect at least 100 000 people worldwide. Mutations in CFTR, the gene encoding the epithelial ion channel that normally transports chloride and bicarbonate, lead to impaired mucus hydration and clearance. Classical cystic fibrosis is thus characterised by chronic pulmonary infection and inflammation, pancreatic exocrine insufficiency, male infertility, and might include several comorbidities such as cystic fibrosis-related diabetes or cystic fibrosis liver disease. This autosomal recessive disease is diagnosed in many regions following newborn screening, whereas in other regions, diagnosis is based on a group of recognised multiorgan clinical manifestations, raised sweat chloride concentrations, or CFTR mutations. Disease that is less easily diagnosed, and in some cases affecting only one organ, can be seen in the context of gene variants leading to residual protein function. Management strategies, including augmenting mucociliary clearance and aggressively treating infections, have gradually improved life expectancy for people with cystic fibrosis. However, restoration of CFTR function via new small molecule modulator drugs is transforming the disease for many patients. Clinical trial pipelines are actively exploring many other approaches, which will be increasingly needed as survival improves and as the population of adults with cystic fibrosis increases. Here, we present the current understanding of CFTR mutations, protein function, and disease pathophysiology, consider strengths and limitations of current management strategies, and look to the future of multidisciplinary care for those with cystic fibrosis.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(20)32542-3

Cites

194 of 194 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Standardisation of spirometry
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Identification of the Cystic Fibrosis Gene: Genetic Analysis
Kerem, B.-S., Rommens, J. M., Buchanan, J. A., Markiewicz, D., Cox, T. K., Chakravarti, A., Buchwald, M., & Tsui, L.-C. (1989) · Science · doi:10.1126/science.2570460 · Cited by 4,142
Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies
Pang, Z., Raudonis, R., Glick, B. R., Lin, T., & Cheng, Z. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.11.013 · Cited by 2,520
Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
Middleton, P. G., Mall, M. A., Dřevínek, P., Lands, L. C., McKone, E. F., Polineni, D., Ramsey, B. W., Taylor-Cousar, J. L., Tullis, E., Vermeulen, F., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908639 · Cited by 2,198
Self-citation
A CFTR Potentiator in Patients with Cystic Fibrosis and the G551D Mutation
Ramsey, B. W., Davies, J., McElvaney, N. G., Tullis, E., Bell, S. C., Dřevínek, P., Griese, M., McKone, E. F., Wainwright, C. E., Konstan, M. W., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105185 · Cited by 2,195
Self-citation
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
Wainwright, C. E., Elborn, J. S., Ramsey, B. W., Marigowda, G., Huang, X., Cipolli, M., Colombo, C., Davies, J. C., De Boeck, K., Flume, P. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1409547 · Cited by 1,622
Self-citation
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
Heijerman, H. G. M., McKone, E. F., Downey, D. G., Van Braeckel, E., Rowe, S. M., Tullis, E., Mall, M. A., Welter, J. J., Ramsey, B. W., McKee, C. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32597-8 · Cited by 1,414
Intermittent Administration of Inhaled Tobramycin in Patients with Cystic Fibrosis
Ramsey, B. W., PEPE, M. S., Quan, J. M., Otto, K., Montgomery, A. B., Williams‐Warren, J., Vasiljev-K, M., Borowitz, D., Bowman, C. M., Marshall, B. C., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400104 · Cited by 1,296
The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart–lung transplantation Report—2019; Focus theme: donor and recipient size match
Chambers, D. C., Cherikh, W. S., Harhay, M. O., Hayes, D., Hsich, E., Khush, K. K., Meiser, B., Potena, L., Rossano, J. W., Toll, A. E., et al. (2019) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2019.08.001 · Cited by 1,269
The future of cystic fibrosis care: a global perspective
Bell, S. C., Mall, M. A., Gutierrez, H., Macek, M., Madge, S. L., Davies, J. C., Burgel, P., Tullis, E., Castaños, C., Castellani, C., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30337-6 · Cited by 1,081
Self-citation

Show all 195 references

Research works printed but not linked: 2

Saunders, 2016, Developments in multibreath washout testing in children with cystic fibrosis, Curr Med Res Opin, 33, 1
2015, Symposium Summaries, Pediatr Pulmonol, 50, S108

Sorted by citations

CRISPR/Cas9 therapeutics: progress and prospects
Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P., & Yu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01309-7 · Cited by 824
Worldwide rates of diagnosis and effective treatment for cystic fibrosis
Guo, J., Garratt, A., & Hill, A. M. (2022) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2022.01.009 · Cited by 395
Physiology and pathophysiology of human airway mucus
Hill, D. B., Button, B. M., Rubinstein, M., & Boucher, R. C. (2022) · Physiological Reviews · doi:10.1152/physrev.00004.2021 · Cited by 406
Cystic Fibrosis
Ong, T., & Ramsey, B. W. (2023) · JAMA · doi:10.1001/jama.2023.8120 · Cited by 346
mRNA vaccines in disease prevention and treatment
Zhang, G., Tang, T., Chen, Y., Huang, X., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01579-1 · Cited by 273
Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications
Shi, Y., Shi, M., Wáng, Y., & You, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02002-z · Cited by 243
Cystic fibrosis
Mall, M. A., Burgel, P., Castellani, C., Davies, J. C., Salathe, M. A., & Taylor‐Cousar, J. L. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00538-6 · Cited by 236
Self-citation
Molecular structures reveal synergistic rescue of Δ508 CFTR by Trikafta modulators
Fiedorczuk, K., & Chen, J. (2022) · Science · doi:10.1126/science.ade2216 · Cited by 176
CFTR modulator therapy: Transforming the landscape of clinical care in cystic fibrosis
Taylor-Cousar, J. L., Robinson, P. D., Shteinberg, M., & Downey, D. G. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01609-4 · Cited by 173
Self-citation
Cathepsin S (CTSS) activity in health and disease - A treasure trove of untapped clinical potential
Smyth, P., Sasiwachirangkul, J., Williams, R. D., & Scott, C. J. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101106 · Cited by 155
The future of cystic fibrosis treatment: from disease mechanisms to novel therapeutic approaches
Graeber, S. Y., & Mall, M. A. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01608-2 · Cited by 147
Future therapies for cystic fibrosis
Allen, L., Allen, L. J., Carr, S. B., Davies, G., Downey, D. G., Egan, M. E., Forton, J. T., Gray, R. D., HAWORTH, C. S., Horsley, A. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36244-2 · Cited by 148
Self-citation
RNA‐based medicine: from molecular mechanisms to therapy
Sparmann, A., & Vogel, J. (2023) · The EMBO Journal · doi:10.15252/embj.2023114760 · Cited by 151
Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials
Mayer-Hamblett, N., Ratjen, F. A., Russell, R., Donaldson, S. H., Riekert, K. A., Sawicki, G. S., Odem‐Davis, K., Young, J., Rosenbluth, D., Taylor‐Cousar, J. L., et al. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00434-9 · Cited by 140
Mesenchymal stem cells in fibrotic diseases—the two sides of the same coin
Qin, L., Liu, N., Bao, C.-L.-M., Yang, D.-Z., Ma, G.-X., Yi, W.-H., Xiao, G.-Z., & Cao, H.-L. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00952-0 · Cited by 114
CFTR function, pathology and pharmacology at single-molecule resolution
Levring, J., Terry, D. S., Kilic, Z., Fitzgerald, G. A., Blanchard, S. C., & Chen, J. (2023) · Nature · doi:10.1038/s41586-023-05854-7 · Cited by 104
In vitro modulator responsiveness of 655 CFTR variants found in people with cystic fibrosis
Bihler, H. J., Sivachenko, A., Millen, L., Bhatt, P., Thakerar, A., Chin, J., Bailey, V., Musisi, I., LaPan, A., Allaire, N., et al. (2024) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2024.02.006 · Cited by 106
Cystic Fibrosis Modulator Therapies
Jia, S., & Taylor‐Cousar, J. L. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-021447 · Cited by 105
Opportunistic Pathogens in Cystic Fibrosis: Epidemiology and Pathogenesis of Lung Infection
Blanchard, A. C., & Waters, V. J. (2022) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piac052 · Cited by 93
Impact of elexacaftor/tezacaftor/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF Registry
Sutharsan, S., Dillenhoefer, S., Welsner, M., Stehling, F., Brinkmann, F., Burkhart, M., Ellemunter, H., Dittrich, A., Smaczny, C., Eickmeier, O., et al. (2023) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2023.100690 · Cited by 78
Recruited monocytes/macrophages drive pulmonary neutrophilic inflammation and irreversible lung tissue remodeling in cystic fibrosis
Öz, H. H., Cheng, E.-C., Pietro, C. D., Tebaldi, T., Biancon, G., Zeiss, C. J., Zhang, P., Huang, P. H., Esquibies, S. S., Britto, C. J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111797 · Cited by 76
Epithelial–Mesenchymal Transition Mechanisms in Chronic Airway Diseases: A Common Process to Target?
Mottais, A., Riberi, L., Falco, A., Soccal, S., Gohy, S. T., & Rose, V. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512412 · Cited by 75
The Changing Epidemiology of Cystic Fibrosis
Burgel, P., Burnet, E., Regard, L., & Martin, C. (2022) · CHEST Journal · doi:10.1016/j.chest.2022.07.004 · Cited by 67
CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France
Regard, L., Martin, C., Burnet, E., Silva, J. D., & Burgel, P. (2022) · Cells · doi:10.3390/cells11111769 · Cited by 72
The Tricky Connection between Extracellular Vesicles and Mitochondria in Inflammatory-Related Diseases
Mambro, T. D., Pellielo, G., Agyapong, E. D., Carinci, M., Chianese, D., Giorgi, C., Morciano, G., Patergnani, S., Pinton, P., & Rimessi, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098181 · Cited by 68
The Impact of Highly Effective Modulator Therapy on Cystic Fibrosis Microbiology and Inflammation
Caverly, L. J., Riquelme, S. A., & Hisert, K. B. (2022) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.06.007 · Cited by 64
Moonlighting chromatin: when DNA escapes nuclear control
Singh, J., Boettcher, M., Dölling, M., Heuer, A., Hohberger, B., Leppkes, M., Naschberger, E., Schapher, M., Schauer, C., Schoen, J., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01124-1 · Cited by 66
Application of a quantitative framework to improve the accuracy of a bacterial infection model
Lewin, G. R., Kapur, A., Cornforth, D. M., Duncan, R. P., Diggle, F. L., Moustafa, D. A., Harrison, S., Skaar, E. P., Chazin, W., Goldberg, J. B., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2221542120 · Cited by 61
Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy
Hisert, K. B., Birket, S. E., Clancy, J. P., Downey, D. G., Engelhardt, J. F., Fajac, I., Gray, R. D., Lachowicz-Scroggins, M. E., Mayer-Hamblett, N., Thibodeau, P. H., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00324-7 · Cited by 65
Impact of Elexacaftor/Tezacaftor/Ivacaftor Therapy on the Cystic Fibrosis Airway Microbial Metagenome
Pallenberg, S. T., Pust, M., Rosenboom, I., Hansen, G., Wiehlmann, L., Dittrich, A., & Tümmler, B. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01454-22 · Cited by 59
Flexible epidermal wearable sensor for Athlete's sweat biomarkers monitoring
Cai, J., Cao, M., Bai, J., Sun, M., Ma, C., Emran, M. Y., Kotb, A., Bo, X., & Zhou, M. (2024) · Talanta · doi:10.1016/j.talanta.2024.126986 · Cited by 59
Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status
Hu, C., Chen, Y., Yin, X., Xu, R., Yin, C., Wang, C., & Zhao, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02098-3 · Cited by 69
The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis
Harvey, C., Weldon, S., Elborn, J. S., Downey, D. G., & Taggart, C. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073513 · Cited by 61
Neutralizing antibodies after nebulized phage therapy in cystic fibrosis patients
Bernabéu-Gimeno, M., Pardo-Freire, M., Chan, B. K., Turner, P. E., Gil-Brusola, A., Pérez‐Tarazona, S., Carrasco‐Hernández, L., Quintana‐Gallego, E., & Domingo‐Calap, P. (2024) · Med · doi:10.1016/j.medj.2024.05.017 · Cited by 57
The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs
Sondo, E., Cresta, F., Pastorino, C., Tomati, V., Capurro, V., Pesce, E., Lena, M., Iacomino, M., Baffico, A. M., Coviello, D. A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063175 · Cited by 58
CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis
Saluzzo, F., Riberi, L., Messore, B., Lorè, N. I., Esposito, I., Bignamini, E., & Rose, V. D. (2022) · Cells · doi:10.3390/cells11071243 · Cited by 58
The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis
Costa, E., Girotti, S., Pauro, F., Leufkens, H. G. M., & Cipolli, M. (2022) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-022-02350-5 · Cited by 57
Exocrine-Endocrine Crosstalk: The Influence of Pancreatic Cellular Communications on Organ Growth, Function and Disease
Overton, D. L., & Mastracci, T. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.904004 · Cited by 55
Antibiotic Resistance in Patients with Cystic Fibrosis: Past, Present, and Future
Perikleous, E. P., Gkentzi, D., Bertzouanis, A., Paraskakis, E., Sovtić, A., & Fouzas, S. (2023) · Antibiotics · doi:10.3390/antibiotics12020217 · Cited by 55
Burkholderia cepacia complex in cystic fibrosis: critical gaps in diagnosis and therapy
Gutiérrez‐Santana, J. C., & Coria‐Jiménez, R. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2307503 · Cited by 55
Organ cross-talk: molecular mechanisms, biological functions, and therapeutic interventions for diseases
Che, H., Gao, Y., Xu, Y., Xu, H., Eils, R., & Tian, M. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02329-1 · Cited by 57
Functional genomics and the future of iPSCs in disease modeling
Brooks, I. R., Garrone, C. M., Kerins, C., Kiar, C. S., Syntaka, S., Xu, J. Z., Spagnoli, F. M., & Watt, F. M. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.03.019 · Cited by 54
Cystic Fibrosis and Oxidative Stress: The Role of CFTR
Moliteo, E., Sciacca, M., Palmeri, A., Papale, M. R., Manti, S., Parisi, G. F., & Leonardi, S. (2022) · Molecules · doi:10.3390/molecules27165324 · Cited by 54
Gene therapy for cystic fibrosis: Challenges and prospects
Sui, H., Xu, X., Su, Y., Gong, Z., Yao, M., Liu, X., Zhang, T., Jiang, Z., Bai, T., Wang, J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1015926 · Cited by 56
Pharmacological Improvement of Cystic Fibrosis Transmembrane Conductance Regulator Function Rescues Airway Epithelial Homeostasis and Host Defense in Children with Cystic Fibrosis
Loske, J., Völler, M., Lukassen, S., Stahl, M., Thürmann, L., Seegebarth, A., Roehmel, J. F., Wisniewski, S., Messingschlager, M., Lorenz, S., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202310-1836oc · Cited by 51
Microbial Epidemiology of the Cystic Fibrosis Airways: Past, Present, and Future
Thornton, C. S., & Parkins, M. D. (2023) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1758732 · Cited by 49
Genetics and epigenetics of chronic rhinosinusitis
Lal, D., Brar, T. K., Ramkumar, S. P., Li, J., Kato, A., & Zhang, L. (2023) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2023.01.004 · Cited by 49
Novel inhalation therapy in pulmonary fibrosis: principles, applications and prospects
Zheng, M., Zhu, W., Gao, F., Zhuo, Y., Mo, Z., Wu, G., & Feng, C. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02407-6 · Cited by 53
Multisystemic Effects of Elexacaftor–Tezacaftor–Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease
Burgel, P., Paillasseur, J.-L., Durieu, I., Reynaud‐Gaubert, M., Hamidfar, R., Murris‐Espin, M., Danner‐Boucher, I., Chiron, R., Leroy, S., Douvry, B., et al. (2024) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202312-1065oc · Cited by 47
Lentiviral Gene Therapy for Cystic Fibrosis: A Promising Approach and First-in-Human Trial
Davies, J. C., Polineni, D., Boyd, A. C., Donaldson, S. H., Gill, D. R., Uta Griesenbach, D., Hyde, S. C., Jain, R., McLachlan, G., Mall, M. A., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202402-0389ci · Cited by 47
Self-citation
Assays of CFTR Function In Vitro, Ex Vivo and In Vivo
Ramalho, A. S., Boon, M., Proesmans, M., Vermeulen, F. L., Carlon, M. S., & Boeck, K. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031437 · Cited by 51
Molecular Prerequisites for Neutrophil Extracellular Trap Formation and Evasion Mechanisms of Staphylococcus aureus
von Köckritz‐Blickwede, M., & Winstel, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.836278 · Cited by 46
CFTR Modulators: Current Status and Evolving Knowledge
Regard, L., Martin, C., Silva, J. D., & Burgel, P. (2022) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0042-1758851 · Cited by 48
SARS-CoV-2 envelope protein impairs airway epithelial barrier function and exacerbates airway inflammation via increased intracellular Cl− concentration
Xu, J.-B., Guan, W., Zhang, Y., Qiu, Z.-E., Chen, L., Hou, X.-C., Yue, J., Zhou, Y.-Y., Sheng, J., Zhao, L., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01753-z · Cited by 44
Prophylactic and therapeutic vaccine development: advancements and challenges
Weerarathna, I. N., Doelakeh, E. S., Kiwanuka, L., Kumar, P., & Arora, S. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00222-x · Cited by 47
The Distribution and Role of the CFTR Protein in the Intracellular Compartments
Łukasiak, A., & Zając, M. (2021) · Membranes · doi:10.3390/membranes11110804 · Cited by 42
Cystic fibrosis transmembrane conductance regulator modulators and the exocrine pancreas: A scoping review
Ramsey, M. L., Li, S. S., Lara, L. F., Gokun, Y., Akshintala, V. S., Conwell, D. L., Heintz, J., Kirkby, S. E., McCoy, K., Papachristou, G. I., et al. (2022) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2022.08.008 · Cited by 43
Ion Channels and Transporters as Therapeutic Agents: From Biomolecules to Supramolecular Medicinal Chemistry
Picci, G., Marchesan, S., & Caltagirone, C. (2022) · Biomedicines · doi:10.3390/biomedicines10040885 · Cited by 41
A succinate/SUCNR1-brush cell defense program in the tracheal epithelium
Perniss, A., Boonen, B., Tonack, S., Thiel, M., Poharkar, K. V., Alnouri, M. W., Keshavarz, M., Papadakis, T., Wiegand, S., Pfeil, U., et al. (2023) · Science Advances · doi:10.1126/sciadv.adg8842 · Cited by 39
Revisiting Host-Pathogen Interactions in Cystic Fibrosis Lungs in the Era of CFTR Modulators
Ribeiro, C. M. P., Higgs, M. G., Muhlebach, M. S., Wolfgang, M. C., Borgatti, M., Lampronti, I., & Cabrini, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24055010 · Cited by 39
Genome Editing for Cystic Fibrosis
Wang, G. (2023) · Cells · doi:10.3390/cells12121555 · Cited by 40
Cystic Fibrosis and Cancer: Unraveling the Complex Role of CFTR Gene in Cancer Susceptibility
Parisi, G. F., Papale, M. R., Pecora, G., Rotolo, N., Manti, S., Russo, G. M., & Leonardi, S. (2023) · Cancers · doi:10.3390/cancers15174244 · Cited by 38
Bicarbonate Transport in Cystic Fibrosis and Pancreatitis
Angyal, D., Bijvelds, M. J. C., Bruno, M. J., Peppelenbosch, M. P., & de Jonge, H. R. (2021) · Cells · doi:10.3390/cells11010054 · Cited by 40
Antisense Oligonucleotide Therapeutics for Cystic Fibrosis: Recent Developments and Perspectives
Kim, Y. J., & Krainer, A. R. (2023) · Molecules and Cells · doi:10.14348/molcells.2023.2172 · Cited by 37
Nutritional Status and Circulating Levels of Fat-Soluble Vitamins in Cystic Fibrosis Patients: A Cohort Study and Evaluation of the Effect of CFTR Modulators
Francalanci, M., Terlizzi, V., Fevola, C., Rosa, G. D., Pierattini, V., Roselli, E., Bonomi, P., Cavicchi, M. C., Galici, V., Neri, A. S., et al. (2023) · Children · doi:10.3390/children10020252 · Cited by 36
Functional restoration of a CFTR splicing mutation through RNA delivery of CRISPR adenine base editor
Amistadi, S., Maule, G., Ciciani, M., Ensinck, M. M., Keersmaecker, L. D., Ramalho, A. S., Guidone, D., Buccirossi, M., Galietta, L. J. V., Carlon, M. S., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.03.004 · Cited by 35
Advancing the pipeline of cystic fibrosis clinical trials: a new roadmap with a global trial network perspective
Mayer-Hamblett, N., Clancy, J. P., Jain, R., Donaldson, S. H., Fajac, I., Goss, C. H., Polineni, D., Ratjen, F. A., Quon, B. S., Zemanick, E. T., et al. (2023) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(23)00297-7 · Cited by 35
Self-citation
Adherence, reliability, and variability of home spirometry telemonitoring in cystic fibrosis
Beaufils, F., Enaud, R., Galodé, F., Boucher, G., Macey, J., Berger, P., Fayon, M. J., & Bui, S. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1111088 · Cited by 34
Cystic fibrosis-related mortality in the United States from 1999 to 2020: an observational analysis of time trends and disparities
Singh, H., Jani, C., Marshall, D. C., Franco, R., Bhatt, P. S., Podder, S., Shalhoub, J., Kurman, J. S., Nanchal, R. S., Uluer, A., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-41868-x · Cited by 33
Challenges of Antimicrobial Resistance and Stewardship in Solid Organ Transplant Patients
So, M., & Walti, L. N. (2022) · Current Infectious Disease Reports · doi:10.1007/s11908-022-00778-1 · Cited by 32
Microevolution of Pseudomonas aeruginosa in the airways of people with cystic fibrosis
Cramer, N., Klockgether, J., & Tümmler, B. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102328 · Cited by 32
Future Comorbidities in an Aging Cystic Fibrosis Population
Ticona, J. H., Lapinel, N. C., & Wang, J. (2023) · Life · doi:10.3390/life13061305 · Cited by 32
Intestinal dysbiosis and inflammation in cystic fibrosis impacts gut and multi-organ axes
Wrigley-Carr, H., van Dorst, J. M., & Ooi, C. Y. (2022) · Medicine in Microecology · doi:10.1016/j.medmic.2022.100057 · Cited by 31
Simultaneous Quantification of Ivacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis Patients’ Plasma by a Novel LC–MS/MS Method
Pigliasco, F., Cafaro, A., Stella, M., Baiardi, G., Barco, S., Pedemonte, N., D’Orsi, C., Cresta, F., Casciaro, R., Castellani, C., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020628 · Cited by 31
Open reading frame correction using splice-switching antisense oligonucleotides for the treatment of cystic fibrosis
Michaels, W. E., Peña‐Rasgado, C., Kotaria, R., Bridges, R. J., & Hastings, M. L. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2114886119 · Cited by 31
Improved Nutritional Outcomes and Gastrointestinal Symptoms in Adult Cystic Fibrosis Patients Treated with Elexacaftor/Tezacaftor/Ivacaftor
Šťastná, N., Kunovský, L., Svoboda, M., Pokojová, E., Homola, L., Malá, M., Gracova, Z., Jeřábková, B., Skřičková, J., & Trna, J. (2024) · Digestive Diseases · doi:10.1159/000538606 · Cited by 30
Nano Approaches to Nucleic Acid Delivery: Barriers, Solutions, and Current Landscape
Gonzalez, J. C., Park, K. W., Evans, D. B., Sharma, R. B., Sahaym, O., Gopalakrishnan, S., Dar, A. I., Valdez, T. A., & Sharma, A. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70010 · Cited by 31
Allergic bronchopulmonary aspergillosis: A multidisciplinary review
Roboubi, A., Audousset, C., Fréalle, É., Brun, A., Laurent, F., Vitte, J., Mortuaire, G., Lefèvre, G., Cadranel, J. L., & Chenivesse, C. (2023) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2023.101392 · Cited by 32
A decade of liver organoids: Advances in disease modeling
Liu, Y., Sheng, J.-Y., Yang, C.-F., Ding, J., & Chan, Y.-S. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0428 · Cited by 30
Pathophysiological role of ion channels and transporters in gastrointestinal mucosal diseases
Deng, Z., Zhao, Y., Ma, Z., Zhang, M., Wang, H., Yi, Z., Tuo, B., Li, T., & Liu, X. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04011-5 · Cited by 29
Disarm The Bacteria: What Temperate Phages Can Do
Zhou, S., Liu, Z., Song, J., & Chen, Y. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45020076 · Cited by 29
Breaching Bacterial Biofilm Barriers: Efficient Combinatorial Theranostics for Multidrug-Resistant Bacterial Biofilms with a Novel Penetration-Enhanced AIEgen Probe
Liu, X., Fan, D., Feng, X., Zheng, Y., Wegner, S. V., Liu, M., Chen, F., & Zeng, W. (2022) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.2c07378 · Cited by 28
Mixed Populations and Co-Infection: Pseudomonas aeruginosa and Staphylococcus aureus
Camus, L., Briaud, P., Vandenesch, F., Doléans-Jordheim, A., & Moreau, K. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-08491-1_15 · Cited by 28
Neutrophil serine proteases in cystic fibrosis: role in disease pathogenesis and rationale as a therapeutic target
Mall, M. A., Davies, J. C., Donaldson, S. H., Jain, R., Chalmers, J. D., & Shteinberg, M. (2024) · European Respiratory Review · doi:10.1183/16000617.0001-2024 · Cited by 27
Self-citation
Mutual Effects of Single and Combined CFTR Modulators and Bacterial Infection in Cystic Fibrosis
Cigana, C., Giannella, R., Colavolpe, A., Alcalá-Franco, B., Mancini, G., Colombi, F., Bigogno, C., Bastrup, U., Bertoni, G., & Bragonzi, A. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.04083-22 · Cited by 28
Folding correctors can restore CFTR posttranslational folding landscape by allosteric domain–domain coupling
Soya, N., Xu, H., Roldán, A., Yang, Z. W., Ye, H., Jiang, F., Premchandar, A., Veit, G., Cole, S. P. C., Kappes, J. C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42586-8 · Cited by 27
Diversity of CFTR variants across ancestries characterized using 454,727 UK biobank whole exome sequences
Ideozu, J. E., Liu, M., Riley-Gillis, B. M., Paladugu, S. R., Rahimov, F., Krishnan, P., Tripathi, R. L., Dorr, P. K., Levy, H., Singh, A. K., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01316-5 · Cited by 29
Channels and Transporters of the Pulmonary Lamellar Body in Health and Disease
Dietl, P., & Frick, M. (2021) · Cells · doi:10.3390/cells11010045 · Cited by 26
A PI3Kγ mimetic peptide triggers CFTR gating, bronchodilation, and reduced inflammation in obstructive airway diseases
Ghigo, A., Murabito, A., Sala, V., Pisano, A. R., Bertolini, S., Gianotti, A., Caci, E., Montresor, A., Premchandar, A., Pirozzi, F., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl6328 · Cited by 26
CFTR mutations and phenotypic correlations in people with cystic fibrosis: a retrospective study from a single centre in south India
Varkki, S. D., Aaron, R., Chapla, A., Danda, S., Medhi, P., Rani, N. J., & Paul, G. (2024) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2024.100434 · Cited by 26
Diversity and prevalence of type VI secretion system effectors in clinical Pseudomonas aeruginosa isolates
Robinson, L. A., Collins, A. C. Z., Murphy, R. A., Davies, J. C., & Allsopp, L. P. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1042505 · Cited by 29
Self-citation
Neutrophil-derived biomarkers in bronchiectasis: identifying a common therapeutic target
Chalmers, J. D., Mall, M. A., Nielsen, K. G., Chang, A. B., Aliberti, S., Blasi, F., Korkmaz, B., Lorent, N., Taggart, C. C., & Loebinger, M. R. (2025) · European Respiratory Journal · doi:10.1183/13993003.00081-2025 · Cited by 25
Clinical outcomes of a large cohort of individuals with the F508del/5T;TG12 CFTR genotype
Tosco, A., Castaldo, A., Colombo, C., Claut, L. E., Carnovale, V., Iacotucci, P., Lucarelli, M., Cimino, G. G., Fabrizzi, B., Caporelli, N., et al. (2022) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2022.04.020 · Cited by 25
Hydrogen Sulfide: A Gaseous Mediator and Its Key Role in Programmed Cell Death, Oxidative Stress, Inflammation and Pulmonary Disease
Zhu, Z., Lian, X., & Bhatia, M. (2022) · Antioxidants · doi:10.3390/antiox11112162 · Cited by 25
Inflammation and Infection in Cystic Fibrosis: Update for the Clinician
Petrocheilou, A., Moudaki, A., & Kaditis, A. G. (2022) · Children · doi:10.3390/children9121898 · Cited by 25
Influence of highly effective modulator therapy on the sputum proteome in cystic fibrosis
Maher, R. E., Barry, P. J., Emmott, E., Jones, A. M., Lijing Lin, A., McNamara, P. S., Smith, J. A., & Lord, R. W. (2023) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2023.10.019 · Cited by 25
Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants
Borgo, C., D’Amore, C., Capurro, V., Tomati, V., Sondo, E., Cresta, F., Castellani, C., Pedemonte, N., & Salvi, M. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04215-3 · Cited by 28
Digestive outcomes in Cystic fibrosis
Ley, D., & Turck, D. (2022) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2022.101788 · Cited by 24
Permeability-driven pressure and cell proliferation control lumen morphogenesis in pancreatic organoids
Lee, B. H., Fuji, K., Petzold, H., Seymour, P. A., Yennek, S., Schewin, C., Lewis, A., Riveline, D., Hiraiwa, T., Sano, M., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01832-5 · Cited by 23
Overview of CF lung pathophysiology
Cabrini, G., Rimessi, A., Borgatti, M., Pinton, P., & Gambari, R. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102214 · Cited by 23

Authors: Shteinberg, M., Haq, I. J., Polineni, D., & Davies, J. C.
Affiliations: Technion – Israel Institute of Technology (IL)
Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
University of Kansas Medical Center (US)
Guy's and St Thomas' NHS Foundation Trust (GB)
ORCID: Shteinberg, Michal
Haq, Iram J
Polineni, Deepika
Davies, Jane C
Venue: The Lancet
Publisher: Elsevier BV
Published: 2021-06
Volume: 397
Issue: 10290
Pages: 2195-2211
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(20)32542-3
OpenAlex: W4205612199
Cited by: 682
References: 195
Citations by year: 2026: 96 · 2025: 132 · 2024: 147 · 2023: 160 · 2022: 131 · 2021: 14
FWCI: 18.21
Type: journal article
Language: en
Open access: green
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
Newcastle University ePrints (Newcastle Univesity)
Funders: National Institute for Health and Care Research (NIHR201402, CL-2018-01-002)
Cystic Fibrosis Trust (SRC 014)
Academy of Medical Sciences (SGL024\1027)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Neonatal Respiratory Health Research
Keywords: cystic fibrosis, CFTR mutations, CFTR function, mucus hydration, chronic lung infection, exocrine pancreatic insufficiency, male infertility, cystic fibrosis-related diabetes, cystic fibrosis liver disease, newborn screening, sweat test, CFTR modulator therapy, mucociliary clearance, disease pathophysiology, multidisciplinary care
MeSH terms: Bicarbonates, Chlorides, Cystic Fibrosis, Humans, Life Expectancy, Mucociliary Clearance, Mutation, Exocrine Pancreatic Insufficiency, Genetic Therapy, Cystic Fibrosis Transmembrane Conductance Regulator, Disease Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cystic fibrosis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Citations

Cites

Cited by

Related

Metadata

Record

About these checks